Immunome Inc. (IMNM)
NASDAQ: IMNMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IMNM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.85B
- EPS (TTM)
- -$2.63
- Dividend yield
- None
- 52-week range
- 15.55 – 30.06
- Day range
- 15.55 – 16.73
- Volume / Avg
- 1.06M / 1.36M
- Beta
- —
- Shares outstanding
- 118.07M
52-week range
IMNM stock today
Immunome (IMNM) closed at $15.69 on Nov 20, down 5.54% (-$0.92), versus the S&P 500's 3.70% decline. Shares are 47.8% below their 52-week high of $30.06, set on Aug 19, 2026 and 0.9% above the 52-week low of $15.55, near the bottom of the past year's range. IMNM is down 27.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 15.3%.
Immunome has posted a net loss over the last twelve months (EPS of -$2.63), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Immunome
Company profileImmunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Clay B. Siegall Ph.D.
- Headquarters
- Bothell, WA
- Employees
- 267
- IPO year
- 2020
- Website
- immunome.com
Financial highlights
Full financialsIn fiscal 2025, Immunome generated $6.9 million in revenue, down 23.2% from fiscal 2024, its first annual decline since 2024. Immunome reported a net loss of $212.4 million, compared with a loss of $293.0 million a year earlier. Operating margin was -3228.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $6.94M | $9.04M | $14.02M | — | — |
| Growth | -23.23% | -35.50% | — | — | — |
| Net income | $-212.39M | $-292.96M | $-106.81M | $-36.90M | $-24.71M |
| EPS (diluted) | $-2.43 | $-5.00 | $-5.38 | $-3.09 | $-2.14 |
Analyst forecast
ForecastConsensus (17 analysts)
strong_buy
Avg. price target
$35.13+123.90%
- Strong buy 3
- Buy 13
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.76 vs $-0.67
- Surprise
- -13.43%
IMNM news
All IMNM news- Immunome, Inc. Reports Third Quarter 2026 Financial Results and Provides Business UpdateNasdaqIMNM, BF.A
- Immunome GAAP EPS of -$0.76 misses by $0.13Seeking Alpha
- Immunome Reports Third Quarter 2026 Financial Results and Provides Business UpdateBusiness Wire
- Immunome stock may move 9.4% on earnings releaseInvesting.com
- 4 Biotech Stocks Likely to Outpace Q3 Earnings EstimatesNasdaqTGTX, RGNX, IMNM, PMN
- William Blair Initiates Coverage of Immunome at OutperformNasdaq
Immunome peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VERAVera Therapeutics Inc. Class A | 25.45 | -4.86% | $1.84B | vs IMNM |
| SEPNSepterna Inc. | 38.61 | -1.51% | $1.84B | vs IMNM |
| BHVNBiohaven Ltd. | 12.39 | -9.23% | $1.87B | vs IMNM |
| MRVIMaravai LifeSciences Holdings Inc. Class A | 6.98 | -2.92% | $1.81B | vs IMNM |
| ZYMEZymeworks Inc. | 26.14 | -2.68% | $1.81B | vs IMNM |
| TRVITrevi Therapeutics Inc. | 13.35 | -2.70% | $1.90B | vs IMNM |
| HRMYHarmony Biosciences Holdings Inc. | 32.59 | -1.18% | $1.91B | vs IMNM |
| ETONEton Pharmaceuticals Inc. | 60.85 | -0.83% | $1.76B | vs IMNM |
Indexes, lists and sector
Immunome stock FAQ
What is Immunome's stock price today?
IMNM last traded at $15.69 as of Nov 20, 4:00 PM EST, down 5.54% on the day. Prices are delayed at least 15 minutes.
Who is Immunome's CEO?
Dr. Clay B. Siegall Ph.D. is the chief executive officer of Immunome Inc., which has about 267 employees.
What is the IMNM 52-week high?
The 52-week high for IMNM is $30.06 and the 52-week low is $15.55. The stock is currently 47.8% below its high.